Hence then, the article about keymed biosciences announces safety and efficacy results of cm313 for primary immune thrombocytopenia published in nejm was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM )
Last updated :
Also on site :
- OPEC+ makes first output decision after UAE exit – Reuters
- Meteorological alert: Temperature drop and unstable weather conditions across Egypt
- We Asked 7 Chefs for Their Favorite Frozen Meals and We're Obsessed With These Answers